TICKERNERD
Menu
PVLAPVLAHealthcare · Biotechnology

PVLA Stock Forecast: Palvella Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$141
+1.25% on the day

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. hold a median 12-month price target of $225 — +59.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.0B
Ticker Nerd rank
31 / 100
Median analyst target
$225
Analysts covering
15
Total return, dividends reinvested
1W
−0.7%
1M
−4.1%
YTD
+34.5%
1Y
+285.2%
From 52W high
−10.5%
From 52W low
+278.4%
$37
$157
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PVLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palvella Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
79
Volatility
72
Quality
51
Accruals
36
Size
36
Revisions
33
Growth
8
Issuance
8

Momentum (96): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Palvella Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

PVLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PVLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26PVLAHigh $270Median $225Low $205

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $205Median $225High $270

The green dot is the last close — the median target sits +59.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 May 2026Chardan CapitalMaintainsBuy$240
21 May 2026Stephens & Co.ReiteratesOverweight$220
12 May 2026Stephens & Co.InitiatesOverweight—
31 Mar 2026Chardan CapitalMaintainsBuy—
24 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
25 Feb 2026BTIGMaintainsBuy—
25 Feb 2026MizuhoMaintainsOutperform—
24 Feb 2026Chardan CapitalMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
16 Jan 2026BTIGReiteratesBuy—
7 Jan 2026MizuhoInitiatesOutperform—
16 Dec 2025Canaccord GenuityMaintainsBuy—
16 Dec 2025Chardan CapitalMaintainsBuy—
16 Dec 2025TD CowenMaintainsBuy—
16 Dec 2025Truist SecuritiesMaintainsBuy—
15 Dec 2025BTIGMaintainsBuy—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Dec 2025BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PVLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
10
Fundamentals

Palvella Therapeutics, Inc. (PVLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.7×

Cheaper than 50% of US stocks

Price / sales
—
Price / book
8.7×

Cheaper than 12% of US stocks

EV / EBITDA
−49.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−34.2%

Higher than 26% of US stocks

Return on assets
−16.6%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PVLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PVLAPalvella Therapeutics, Inc.$2.0B
31
ZBIOZenas BioPharma, Inc.$2.0B
30
AUPHAurinia Pharmaceuticals, Inc.$2.0B
98
ADMAADMA Biologics, Inc.$2.0B
34
BHVNBiohaven Ltd.$2.0B
18
HRMYHarmony Biosciences Holdings, Inc.$2.0B
85
KARDKardigan, Inc.$1.9B
1
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PVLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PVLA news & analysis

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

GlobeNewsWire · 30 July 2026positive

Palvella Therapeutics' Chief Scientific Officer, Jeff Martini, Ph.D., has been selected to present at an upcoming FDA Public Workshop on Drug Repurposing scheduled for August 5th.

Why it matters — Selection to present at an FDA public workshop signals that Palvella's scientific leadership and expertise in drug development are being recognized at the regulatory level.

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

GlobeNewsWire · 28 July 2026neutral

Palvella Therapeutics announced it will report its second quarter 2026 financial results before market open on August 4, 2026, and will host a conference call at 8:30 a.m. ET that same day to discuss the results and provide a corporate update.

Why it matters — The conference call and financial results will give investors insight into Palvella's recent performance and an update on its pipeline of therapies for rare skin diseases and vascular malformations.

FAQ

Frequently asked questions about PVLA stock

What is the PVLA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. have a median 12-month price target of $225, with estimates ranging from $205 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PVLA stock a buy right now?

Of the 15 analysts covering Palvella Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palvella Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PVLA?

As at 1 Aug 2026, Palvella Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will PVLA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +59.8% from the last close, and Ticker Nerd's factor model ranks Palvella Therapeutics, Inc. 31 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PVLA stock forecast for 2030?

No analyst covering Palvella Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PVLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $205 to $270 over the next 12 months.

How has PVLA stock performed over the past year?

Palvella Therapeutics, Inc. returned +285.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palvella Therapeutics, Inc. do?

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders.

What is the latest news on PVLA?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing". Palvella Therapeutics' Chief Scientific Officer, Jeff Martini, Ph.D., has been selected to present at an upcoming FDA Public Workshop on Drug Repurposing scheduled for August 5th.

Company

About Palvella Therapeutics, Inc.

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The primary function of the company is to research and advance treatments that address unmet medical needs in the realm of genetic diseases, leveraging advanced biotechnological innovations. The company plays a significant role in the health care and pharmaceutical sectors, differentiating itself with its commitment to precision medicine approaches and personalized therapies. By concentrating on niche areas that are often overlooked by larger pharmaceutical firms, Pavella Therapeutics Inc. aims to provide hope and potential treatment options to patients with limited alternatives. In the financial markets, Pavella Therapeutics holds a distinctive position as a cutting-edge firm with the potential to drive significant impacts within its specialized domain. The company's activities contribute to the broader biotechnology landscape by enhancing understanding of genetic conditions and supporting the development of targeted biotherapeutic solutions.

CEO Mr. Wesley H. Kaupinen · 29 employees · United States · https://palvellatx.com